样式: 排序: IF: - GO 导出 标记为已读
-
Do placebos harm patients in IBD trials? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-19 Fernando Gomollón
-
Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-19 Shahida Din,Jonathan Segal,Jonathan Blackwell,Beatriz Gros,Christopher J Black,Alexander C Ford
BACKGROUND Randomised placebo-controlled trials are the gold standard to assess novel drugs in ulcerative colitis and Crohn's disease. However, there might be risks associated with receiving placebo. We aimed to examine the harms associated with receiving placebo in trials of licensed biologics and small molecules for the induction of remission in ulcerative colitis and luminal Crohn's disease in a
-
Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-19 Beatriz Gros,Jonathan Blackwell,Jonathan Segal,Christopher J Black,Alexander C Ford,Shahida Din
BACKGROUND Randomised placebo-controlled trials for the induction of inflammatory bowel disease (IBD) remission involve potential harms to those receiving placebo. Whether these harms are also apparent with placebo during maintenance of remission trials in IBD is unclear. We aimed to examine the potential harms associated with receiving placebo in trials of licensed biologics and small molecules for
-
Availability of point-of-care HBV tests in resource-limited settings. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-18 Daryl T Y Lau,Kathy Jackson,Camila A Picchio,Anna Kramvis,Mark Sonderup,Maud Lemoine,Gail Matthews,Jessica Howell,Carla S Coffin,Margaret Hellard,Alice U Lee,David A Anderson,Helene A Kerth,El Eunyoung Lee,John E Tavis,Maura Dandri,Peter A Revill,C Wendy Spearman,Capucine Penicaud,Massimo Levrero,Manal El-Sayed,
-
Is computer-aided diagnosis living up to its promise? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-17 Quirine E W van der Zander
-
Computer-aided diagnosis for the resect-and-discard strategy for colorectal polyps: a systematic review and meta-analysis. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-17 Cesare Hassan,Tommy Rizkala,Yuichi Mori,Marco Spadaccini,Masashi Misawa,Giulio Antonelli,Emanuele Rondonotti,Evelien Dekker,Britt B S L Houwen,Oliver Pech,Sebastian Baumer,James Weiquan Li,Daniel von Renteln,Claire Haumesser,Roberta Maselli,Antonio Facciorusso,Loredana Correale,Maddalena Menini,Alessandro Schilirò,Kareem Khalaf,Harsh Patel,Dhruvil K Radadiya,Pradeep Bhandari,Shin-Ei Kudo,Shahnaz Sultan
BACKGROUND The resect-and-discard strategy allows endoscopists to replace post-polypectomy pathology with real-time prediction of polyp histology during colonoscopy (optical diagnosis). We aimed to investigate the benefits and harms of implementing computer-aided diagnosis (CADx) for polyp pathology into the resect-and-discard strategy. METHODS In this systematic review and meta-analysis, we searched
-
Global differences in the management of alcohol-associated hepatitis. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-10 Hanna Blaney,Luis Antonio Díaz,Nhi Li,Gurpreet Malhi,Rokhsana Mortuza,Xiaolong Qi,Anand V Kulkarni,Ramon Bataller,Joaquin Cabezas,Alexandre Louvet,Elliot B Tapper,Juan Pablo Arab
-
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Yuan Sun,Yan Li,Kezhen Zong,Ning Jiang,Baoyong Zhou
-
Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Hannes Hagström,Ying Shang,Hannes Hegmar,Patrik Nasr
The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. A minority of patients develop inflammation and risk progressive fibrosis that can result in cirrhosis. Progression to cirrhosis occurs in 3-5% of patients and often takes more than 20 years. This narrative review presents
-
Irritable bowel syndrome: an urgent issue. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Chrissie Pearson
-
Blood tests for colorectal cancer: practical or premature? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 The Lancet Gastroenterology Hepatology
-
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? - Author's reply. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Eduard A van Bodegraven,Alberto Balduzzi,Tess M E van Ramshorst,Giuseppe Malleo,Frederique L Vissers,Jony van Hilst,Giovanni Marchegiani,Matteo de Pastena,Roberto Salvia,Casper H J van Eijck,Marc G Besselink,
-
Augmenting colonoscopy with AI: insights and future directions. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Sravanthi Parasa
-
Regional disparities of infections in cirrhosis: a call for action. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-04 Nipun Verma,Salvatore Piano
-
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-04 Zhujun Cao,Florence Wong,Ashok K Choudhury,Patrick S Kamath,Mark Topazian,Aldo Torre,Peter C Hayes,Jacob George,Ramazan Idilman,Wai-Kay Seto,Hailemichael Desalegn,Mario Reis Alvares-da-Silva,Brian J Bush,Leroy R Thacker,Qing Xie,Jasmohan S Bajaj,
BACKGROUND Infections have a poor prognosis in inpatients with cirrhosis. We aimed to determine regional variations in infections and their association with clinical outcomes in a global cohort of inpatients with cirrhosis. METHODS In this prospective cohort study initiated by the CLEARED Consortium, we enrolled adults (aged >18 years) with cirrhosis who were non-electively admitted to 98 hospitals
-
Best buy interventions to address the burden of steatotic liver disease. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-03 Jeffrey V Lazarus,Henry E Mark,Naim Alkhouri,Luis Antonio Díaz,Ajay Duseja,C Wendy Spearman,Maja Thiele,Vincent Wai-Sun Wong,Zobair M Younossi
-
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-02 Matthew C Choy,Christopher F D Li Wai Suen,Danny Con,Kristy Boyd,Raquel Pena,Kathryn Burrell,Ourania Rosella,David Proud,Richard Brouwer,Alexandra Gorelik,Danny Liew,William R Connell,Emily K Wright,Kirstin M Taylor,Aviv Pudipeddi,Michelle Sawers,Britt Christensen,Watson Ng,Jakob Begun,Graham Radford-Smith,Mayur Garg,Neal Martin,Daniel R van Langenberg,Nik S Ding,Lauren Beswick,Rupert W Leong,Miles
BACKGROUND The optimal dosing strategy for infliximab in steroid-refractory acute severe ulcerative colitis (ASUC) is unknown. We compared intensified and standard dose infliximab rescue strategies and explored maintenance therapies following infliximab induction in ASUC. METHODS In this open-label, multicentre, randomised controlled trial, patients aged 18 years or older from 13 Australian tertiary
-
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-02 Saurabh Kedia,Vineet Ahuja
-
Optimising local treatment decisions for rectal cancer. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Krishan R Jethwa,Khush S Aujla,Aurelie Garant
-
Normothermic regional perfusion presents ethical concerns in the USA. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Bryant Furlow
-
Expression of concern-Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 The Editors Of The Lancet Gastroenterology Hepatology
-
Diet or optimised medical therapy for people with irritable bowel syndrome. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Alexander C Ford,Christopher J Black,Michael Camilleri
-
Watch and wait for rectal cancer: towards data-informed surveillance. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Fahima Dossa,Martin R Weiser
-
Diet or optimised medical therapy for people with irritable bowel syndrome. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Christian Lambiase,Giuseppe Chiarioni,Massimo Bellini
-
Diet or optimised medical therapy for people with irritable bowel syndrome - Authors' reply. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Sanna Nybacka,Hans Törnblom,Axel Josefsson,Johann P Hreinsson,Lena Böhn,Åsa Frändemark,Cecilia Weznaver,Stine Störsrud,Magnus Simrén
-
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer - Authors' reply. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Durgesh Wankhede,Michael Hoffmeister
-
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 Changjing Cai,Peng Zhang,Ying Han,Hong Shen,Shan Zeng
-
Global progress towards alcohol harm reduction insufficient. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-01 The Lancet Gastroenterology Hepatology
-
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-08-16 Klara Dorman MD, Prof Stefan Boeck MD, Prof Karel Caca MD, Prof Maximilian Reichert MD, Thomas J Ettrich MD, Prof Helmut Oettle MD, Prof Oliver Waidmann MD, Prof Dominik P Modest MD, Lothar Müller MD, Prof Patrick Michl MD, Prof Stephan Kanzler MD, Daniel Pink MD, Prof Anke Reinacher-Schick MD, Prof Michael Geißler MD, Henning Pelz MD, Prof Volker Kunzmann MD, Swantje Held MSc, Thomas Schichtl MD,
A standardised dose-reduction strategy has not been established for the widely used gemcitabine plus nab-paclitaxel regimen in patients with metastatic pancreatic ductal adenocarcinoma. We aimed to investigate the efficacy and tolerability of alternating treatment cycles of nab-paclitaxel–gemcitabine combination therapy and gemcitabine alone versus continuous treatment with the nab-paclitaxel–gemcitabine
-
Metastatic pancreatic cancer: a new standardised dose-reduction regimen? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-08-16 Paula Ghaneh, Daniel Palmer
-
Polyp detection with colonoscopy assisted by the GI Genius artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, pragmatic randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-08-14 Alexander Seager MSc, Prof Linda Sharp PhD, Laura J Neilson MD, Andrew Brand PhD, James S Hampton MBBS, Tom J W Lee MD, Rachel Evans MSc, Prof Luke Vale PhD, John Whelpton, Nathania Bestwick MSc, Prof Colin J Rees FRCP, COLO-DETECT trial team, Neil Cripps, John Greenaway, Andrew Higham, John Jacob, Aravinth Murugananthan, David Nylander, Panna Patel, Salil Singh, Ajay M Verma
Increased polyp detection during colonoscopy is associated with decreased post-colonoscopy colorectal cancer incidence and mortality. The COLO-DETECT trial aimed to assess the clinical effectiveness of the GI Genius intelligent endoscopy module for polyp detection, comparing colonoscopy assisted by GI Genius (computer-aided detection [CADe]-assisted colonoscopy) with standard colonoscopy in routine
-
The promise of indocyanine green in colorectal surgery Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-08-13 Zoe Garoufalia
-
Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-08-13 Robin A Faber MD, Ruben P J Meijer MD, Daphne H M Droogh MD, Jasmijn J Jongbloed BSc, Okker D Bijlstra MD, Fran Boersma BSc, Jeffrey P B M Braak BSc, Elma Meershoek-Klein Kranenbarg MSc, Prof Hein Putter MD PhD, Fabian A Holman MD PhD, J Sven D Mieog MD PhD, Peter A Neijenhuis MD, Esther van Staveren, Johanne G Bloemen MD PhD, Jacobus W A Burger MD PhD, Tjeerd S Aukema MD PhD, Mark A M Brouwers MD
Anastomotic leakage is a severe postoperative complication in colorectal surgery and compromised bowel perfusion is considered a major contributing factor. Conventional methods to assess bowel perfusion have a low predictive value for anastomotic leakage. We therefore aimed to evaluate the efficacy of real-time assessment with near-infrared (NIR) fluorescence imaging with indocyanine green (ICG) in
-
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-08-01 Ryan J Jalleh PhD, Prof Chris K Rayner PhD, Prof Trygve Hausken PhD, Prof Karen L Jones PhD, Prof Michael Camilleri MD, Prof Michael Horowitz DSc
The availability of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as liraglutide and semaglutide, and a GLP-1 and glucose dependent insulinotropic polypeptide coagonist (tirzepatide) represents a paradigm shift in the management of both type 2 diabetes and obesity. There is now considerable attention, including in the public media, on the effect of both long-acting and short-acting GLP-1RAs
-
Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-08-01 Jasmijn Maria Westerhoff,Nina Niu Sanford,William Adrian Hall
-
Time for a treat all approach for hepatitis B. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-08-01 Rachel Halford,Danjuma Adda,Jessica Hicks,Cary James,Alexandra Smith
-
Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-08-01 Florentine E F Timmer,Bart Geboers,Hester J Scheffer,Anna M E Bruynzeel,Martijn R Meijerink,
-
The need for affordable, pragmatic, investigator-led clinical trials of treatment strategies in inflammatory bowel disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-31 Nurulamin M Noor, Shaji Sebastian, Miles Parkes, Tim Raine
-
Viral hepatitis: time for action Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-26 The Lancet Gastroenterology & Hepatology
-
Brief sigmoidoscopy provides 21-year colorectal cancer risk reduction in men Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-20 Michael Bretthauer, Nastazja D Pilonis
-
Long-term effects of once-only flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: 21-year follow-up of the UK Flexible Sigmoidoscopy Screening randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-20 Kate Wooldrage MSc, Emma C Robbins MSc, Prof Stephen W Duffy MSc, Prof Amanda J Cross PhD
Flexible sigmoidoscopy screening reduces colorectal cancer incidence and mortality; however, uncertainty exists about the duration of protection and differences by sex and age. We assessed effects of once-only flexible sigmoidoscopy screening after 21 years' follow-up. The UK Flexible Sigmoidoscopy Screening Trial is a multicentre randomised controlled trial that recruited men and women aged 55–64
-
Artificial intelligence-assisted adenoma detection in people with Lynch syndrome Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-19 Carol A Burke, Carole Macaron, Aparajita Singh
-
An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-19 Oswaldo Ortiz MD, Maria Daca-Alvarez MD, Liseth Rivero-Sanchez PhD, Antonio Z Gimeno-Garcia PhD, Marta Carrillo-Palau PhD, Victoria Alvarez MD, Alejandro Ledo-Rodriguez PhD, Prof Luigi Ricciardiello MD, Chiera Pierantoni MD, Robert Hüneburg MD, Prof Jacob Nattermann PhD, Prof Raf Bisschops PhD, Sabine Tejpar PhD, Alain Huerta MSc, Faust Riu Pons PhD, Cristina Alvarez-Urturi PhD, Jorge López-Vicente
Computer-aided detection (CADe) systems for colonoscopy have been shown to increase small polyp detection during colonoscopy in the general population. People with Lynch syndrome represent an ideal target population for CADe-assisted colonoscopy because adenomas, the primary cancer precursor lesions, are characterised by their small size and higher likelihood of showing advanced histology. We aimed
-
Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021 Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-17 GBD 2021 Appendicitis Collaborator Group, Hannah Han, Ian D Letourneau, Yohannes Habtegiorgis Abate, Michael Abdelmasseh, Eman Abu-Gharbieh, Tigist Demssew Adane, Bright Opoku Ahinkorah, Aqeel Ahmad, Ali Ahmadi, Ayman Ahmed, Fadwa Naji Alhalaiqa, Salman Khalifah Al-Sabah, Yaser Mohammed Al-Worafi, Hubert Amu, Catalina Liliana Andrei, Amir Anoushiravani, Jalal Arabloo, Aleksandr Y Aravkin, Tahira Ashraf
-
Hepatitis C epidemic among Rohingya refugees in Cox's Bazar: a public health emergency Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-16 Udani Samarasekera
-
Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-15 Benjamin Click, Stefan D Holubar
-
Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-15 Eline M L van der Does de Willebois MD, Vittoria Bellato MD, Marjolijn Duijvestein MD, Jarmila D W van der Bilt MD, Koen van Dongen MD, Prof Antonino Spinelli MD, Prof Geert R D'Haens MD, Marco W Mundt MD, Federica Furfaro MD, Prof Silvio Danese MD, Prof Andrea Vignali MD, Prof Willem A Bemelman MD, Christianne J Buskens MD, SPICY collaborator group, Michele Carvello, Susan Van Dieren, Alice Frontali
Retrospective research suggests that excision of the affected mesentery can improve outcomes after an ileocoecal resection in Crohn's disease. However, prospective data from randomised controlled trials are scarce. We aimed to compare rates of postoperative recurrence in patients with Crohn's disease who underwent extended mesenteric resection. This international, randomised controlled trial was done
-
Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-09 Prof Laure Elkrief, Virginia Hernandez-Gea, Marco Senzolo, Prof Agustin Albillos, Anna Baiges, Prof Annalisa Berzigotti, Prof Christophe Bureau, Sarwa Darwish Murad, Prof Andrea De Gottardi, Prof François Durand, Juan-Carlos Garcia-Pagan, Prof Ton Lisman, Mattias Mandorfer, Prof Valérie McLin, Lucile Moga, Filipe Nery, Prof Patrick Northup, Alexandre Nuzzo, Prof Valérie Paradis, Prof David Patch, Audrey
Portal vein thrombosis (PVT) refers to the development of a non-malignant obstruction of the portal vein, its branches, its radicles, or a combination. This Review first provides a comprehensive overview of all aspects of PVT, namely the specifics of the portal venous system, the risk factors for PVT, the pathophysiology of portal hypertension in PVT, the interest in non-invasive tests, as well as
-
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-01 Rirong Chen,Shenghong Zhang
-
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-01 Jack Satsangi,Jan Nowak,Rahul Kalla,Jean-Frederic Colombel
-
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-01 Vinay Borkar,Yatin Lunagariya,Shivani Chopra,Deepak Sasikumar,Meghraj Ingle
-
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-07-01 Arno R Bourgonje,Marijn C Visschedijk,Eleonora A M Festen,Rinse K Weersma,Gerard Dijkstra
-
Breaking down barriers between liver, addiction, and mental health services for people with alcohol-related liver disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-25 Ashwin D Dhanda, Victoria Allgar, Neeraj Bhala, Lynne Callaghan, Joana Castro, Shilpa Chokshi, Amanda Clements, Colin Drummond, Ewan H Forrest, Lesle Manning, Richard Parker, Debbie L Shawcross, Jennifer Towey
-
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-18 Maeve A Lowery
-
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-18 Prof Yoon-Koo Kang MD, Masanori Terashima MD, Young-Woo Kim MD, Prof Narikazu Boku MD, Prof Hyun Cheol Chung MD, Prof Jen-Shi Chen MD, Jiafu Ji MD, Ta-Sen Yeh MD, Prof Li-Tzong Chen MD, Prof Min-Hee Ryu MD, Jong Gwang Kim MD, Takeshi Omori MD, Prof Sun Young Rha MD, Tae Yong Kim MD, Keun Won Ryu MD, Prof Shinichi Sakuramoto MD, Yasunori Nishida MD, Norimasa Fukushima MD, Takanobu Yamada MD, Li-Yuan
In Asia, adjuvant chemotherapy after gastrectomy with D2 or more extensive lymph-node dissection is standard treatment for people with pathological stage III gastric or gastro-oesophageal junction (GEJ) cancer. We aimed to assess the efficacy and safety of adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy administered in this setting. ATTRACTION-5 was a randomised, multicentre,
-
Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-17 Lung-Yi Mak
-
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-17 Prof Harry L A Janssen MD, Prof Young-Suk Lim MD, Prof Pietro Lampertico MD, Prof Jeong Heo MD, Chi-Yi Chen MD, Claire Fournier MD, Tak Yin Owen Tsang MD, Ho Bae MD, Chien-Hung Chen MD, Prof Carla S Coffin MD, Sang Hoon Ahn MD, Huy Trinh MD, John F Flaherty PharmD, Frida Abramov DMSc, Yang Zhao PhD, Yang Liu PhD, Audrey Lau MD, Polina German PharmD, Prof Wan-Long Chuang MD, Kosh Agarwal MD, Prof Edward
Phase 3 studies in patients with chronic hepatitis B have shown tenofovir alafenamide to have non-inferior efficacy to tenofovir disoproxil fumarate, with improved renal and bone safety. We conducted this study to evaluate the safety and efficacy of switching to tenofovir alafenamide in participants with chronic hepatitis B and renal or hepatic impairment. This open-label, multicentre, phase 2 study
-
No accident: the UK infected blood scandal Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-13 The Lancet Gastroenterology & Hepatology
-
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-12 Renée Duijzer MD, Lucas H P Bernts MD PhD, Anja Geerts MD PhD, Bart van Hoek PhD, Prof Minneke J Coenraad MD PhD, Prof Chantal Rovers PhD, Domenico Alvaro MD, Prof Ed J Kuijper MD PhD, Prof Frederik Nevens MD PhD, Jan Halbritter MD, Prof Jordi Colmenero PhD, Prof Juozas Kupcinskas MD PhD, Mahdi Salih MD PhD, Prof Marie C Hogan MD PhD, Maxime Ronot PD PhD, Prof Valerie Vilgrain PhD, Nicolien M Hanemaaijer
Liver cyst infections often necessitate long-term hospital admission and are associated with considerable morbidity and mortality. We conducted a modified Delphi study to reach expert consensus for a clinical decision framework. The expert panel consisted of 24 medical specialists, including 12 hepatologists, from nine countries across Europe, North America, and Asia. The Delphi had three rounds. The
-
Nanoliposomal irinotecan in advanced biliary tract cancers Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-06-10 David Malka, Raphaël Colle